Wealth Alliance Has $318,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Wealth Alliance decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% in the 4th quarter, HoldingsChannel reports. The firm owned 1,722 shares of the medical research company’s stock after selling 183 shares during the period. Wealth Alliance’s holdings in Charles River Laboratories International were worth $318,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in CRL. Creative Planning lifted its holdings in Charles River Laboratories International by 4.0% during the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock valued at $920,000 after purchasing an additional 180 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter valued at $83,800,000. Assenagon Asset Management S.A. lifted its holdings in Charles River Laboratories International by 152.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 49,030 shares of the medical research company’s stock valued at $9,657,000 after purchasing an additional 29,621 shares during the last quarter. E. Ohman J or Asset Management AB acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $158,000. Finally, Forsta AP Fonden lifted its holdings in shares of Charles River Laboratories International by 11.6% during the third quarter. Forsta AP Fonden now owns 10,600 shares of the medical research company’s stock worth $2,088,000 after buying an additional 1,100 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 0.5 %

CRL stock opened at $163.11 on Friday. The firm has a 50-day moving average price of $172.84 and a 200-day moving average price of $188.37. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $275.00. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm’s revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO James C. Foster bought 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on CRL. UBS Group reaffirmed a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).